Published in Arch Intern Med on June 09, 2003
Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. Blood Transfus (2011) 0.95
Symptomatic venous thromboembolism and mortality in orthopaedic surgery - an observational study of 45 968 consecutive procedures. BMC Musculoskelet Disord (2013) 0.95
Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study. Int Orthop (2012) 0.88
The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol (2005) 0.80
Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery. Thromb J (2015) 0.75
Are we missing post-thrombotic syndrome syndrome? An orthopaedic perspective in lower limb arthroplasty. Thrombosis (2011) 0.75
[Prevention of venous thromboembolism in musculoskeletal surgery]. Wien Klin Wochenschr (2014) 0.75
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med (2003) 7.15
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst (2002) 4.33
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med (2011) 2.65
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst (2003) 2.51
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol (2006) 2.23
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Clonidine in patients undergoing noncardiac surgery. N Engl J Med (2014) 2.07
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med (2006) 1.78
Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med (2003) 1.75
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.74
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med (2003) 1.70
Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med (2007) 1.70
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol (2003) 1.67
Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys (2009) 1.63
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. Thromb Haemost (2008) 1.50
Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49
Guidelines for anticoagulant use in acute coronary syndromes. Lancet (2008) 1.49
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest (2005) 1.49
Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. J Vasc Surg (2011) 1.48
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46
Should patients with stroke wear compression stockings to prevent venous thromboembolism? Ann Intern Med (2010) 1.42
Deep venous thrombosis. Hematology Am Soc Hematol Educ Program (2004) 1.41
Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.39
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest (2003) 1.36
Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol (2002) 1.34
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med (2008) 1.33
Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood (2003) 1.31
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med (2010) 1.27
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.21
Early postoperative anticoagulation after mechanical valve replacement: a systematic review. Ann Thorac Surg (2006) 1.14
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest (2003) 1.08
Establishing an optimal therapeutic range for coumarins: filling in the gaps. Arch Intern Med (2004) 1.07
Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. Chest (2009) 1.03
The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion (2012) 1.03
Physical activity in patients with deep venous thrombosis: a systematic review. Thromb Res (2007) 1.02
Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Investig Drugs (2007) 0.99
Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med (2015) 0.99
Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med (2007) 0.97
Development of a research agenda for inferior vena cava filters: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol (2009) 0.93
Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost (2006) 0.93
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation (2003) 0.90
Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost (2006) 0.90
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis (2013) 0.89
HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med (2008) 0.89
Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines. Chest (2008) 0.88
Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood (2013) 0.87
Electrical foot stimulation and implications for the prevention of venous thromboembolic disease. Thromb Haemost (2002) 0.86
Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. CMAJ (2010) 0.84
New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol (2010) 0.84
Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg (2004) 0.83
Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis. Thromb Res (2005) 0.83
Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation (2009) 0.82
Predictors of thrombosis in relatives of patients with venous thromboembolism. Curr Opin Pulm Med (2010) 0.82
In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res (2002) 0.82
New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 0.82
Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program (2003) 0.82
Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism. Arterioscler Thromb Vasc Biol (2013) 0.81
Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol (2013) 0.81
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost (2010) 0.81
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost (2014) 0.81